Insider Selling: RxSight, Inc. (NASDAQ:RXST) Insider Sells $151,962.00 in Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $49.02, for a total value of $151,962.00. Following the sale, the insider now owns 42,246 shares in the company, valued at approximately $2,070,898.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $49.29, for a total transaction of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $53.19, for a total transaction of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The stock was sold at an average price of $39.25, for a total value of $353,250.00.

RxSight Stock Performance

Shares of NASDAQ RXST opened at $47.56 on Thursday. The company has a market capitalization of $1.76 billion, a PE ratio of -37.75 and a beta of 1.22. The company’s fifty day moving average price is $51.16 and its 200 day moving average price is $53.86. RxSight, Inc. has a 1 year low of $20.66 and a 1 year high of $66.54.

RxSight (NASDAQ:RXST) last posted its earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. The firm had revenue of $34.89 million for the quarter, compared to analysts’ expectations of $32.33 million. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The company’s quarterly revenue was up 67.6% on a year-over-year basis. During the same period last year, the firm earned ($0.40) EPS. On average, equities analysts expect that RxSight, Inc. will post -0.81 EPS for the current year.

Institutional Trading of RxSight

Several institutional investors have recently bought and sold shares of the business. Marshall Wace LLP purchased a new position in shares of RxSight during the 2nd quarter valued at approximately $19,512,000. Driehaus Capital Management LLC raised its position in RxSight by 74.9% during the second quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock worth $42,490,000 after acquiring an additional 302,367 shares during the period. Baillie Gifford & Co. lifted its holdings in RxSight by 438.8% during the second quarter. Baillie Gifford & Co. now owns 358,215 shares of the company’s stock valued at $21,554,000 after purchasing an additional 291,733 shares in the last quarter. William Blair Investment Management LLC acquired a new stake in shares of RxSight in the second quarter valued at about $14,942,000. Finally, M&G Plc purchased a new stake in shares of RxSight during the first quarter worth about $7,354,000. 78.78% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RXST has been the topic of a number of research reports. Stifel Nicolaus cut their price objective on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and issued a $66.00 price target on shares of RxSight in a report on Friday, September 13th. BTIG Research lifted their price objective on shares of RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Wells Fargo & Company cut their price objective on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Finally, Oppenheimer decreased their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research report on Tuesday, August 6th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $60.14.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.